Latest Commercialization News

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Almonty Industries has commenced commercial production at its flagship Sangdong Mine in South Korea and secured more than US$200 million through Nasdaq IPO and equity offerings to fund expansion projects. Despite rising revenues driven by soaring tungsten prices, the company reported a significant net loss due to non-cash derivative liabilities.

Diatreme Resources has reported a significant boost in mineral recoveries and production forecasts for its Cyclone Project in Western Australia, driven by advanced metallurgical testwork and flowsheet optimisation.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Tesoro Gold Limited has expanded the El Zorro Gold Project’s known gold corridor by 10 kilometres following a high-resolution helicopter survey and soil sampling, revealing multiple new drill targets across a 40km structural corridor in Chile.

Hazer Group has inked a non-binding graphite offtake agreement with Green Steel of WA, marking a significant step in supplying low-emission steel production with up to 85,000 tonnes over 10 years.

Lakes Blue Energy has temporarily halted gas flow testing at its Wombat-5 well to conduct extended pressure analysis, planning a perforation program to enhance production prospects.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Immutep Limited has successfully completed the single ascending dose phase of its IMP761 trial, showing promising safety and immunosuppressive effects in healthy volunteers. The biotech’s novel LAG-3 agonist could reshape autoimmune disease treatment.